<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">HER inhibitor</span> <span style="margin-left: 1em;">EGFR inhibitor</span> <span style="margin-left: 2em;">cetuximab based chemotherapy</span> <span style="margin-left: 3em;">cetuximab plus platin plus 5FU <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-CTLA-4</span> <span style="margin-left: 2em;">tremelimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">durvalumab based treatment</span> <span style="margin-left: 3em;">durvalumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">pembrolizumab plus 5FU plus platin <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">Immune checkpoint association</span> <span style="margin-left: 2em;">durvalumab plus tremelimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (13) progression or deaths (PFS) (13) objective responses (ORR) (13) DOR (12) DCR (4) deaths (OS) (extension) (4) PFS (extension) (1) objective responses (ORR) (extension) (1) TRAE (any grade) (9) TRAE leading to death (grade 5) (9) TRAE (grade 3-4) (7) AE leading to treatment discontinuation (any grade) (6) TRAE leading to discontinuation (any grade) (6) AE leading to death (grade 5) (4) AE (any grade) (3) AE (grade 3-4) (3) SAE (any grade) (2) STRAE (any grade) (2) TRAE leading to discontinuation (grade 3-4) (1) Diarrhoea TRAE (grade 3-4) (8) Fatigue TRAE (grade 3-4) (8) Anaemia TRAE (grade 3-4) (8) Asthenia TRAE (grade 3-4) (8) Nausea TRAE (grade 3-4) (6) Decreased appetite TRAE (grade 3-4) (6) Thrombocytopenia TRAE (grade 3-4) (6) Neutropenia TRAE (grade 3-4) (6) Leucopenia TRAE (grade 3-4) (6) Mucosal inflammation TRAE (grade 3-4) (6) Stomatitis TRAE (grade 3-4) (6) Rash TRAE (grade 3-4) (5) Hypothyroidism TRAE (grade 3-4) (5) Pruritus TRAE (grade 3-4) (4) Increased ALT TRAE (grade 3-4) (4) Alopecia TRAE (grade 3-4) (4) Pneumonitis TRAE (grade 3-4) (5) Peripheral neuropathy TRAE (grade 3-4) (3) Infusion-related reactions TRAE (grade 3-4) (5) Colitis TRAE (grade 3-4) (4) Hepatitis TRAE (grade 3-4) (4) Hyperthyroidism TRAE (grade 3-4) (4) Adrenal insufficiency TRAE (grade 3-4) (4) Skin and subcutaneous tissue disorders TRAE (grade 3-4) (4) Endocrine disorders TRAE (grade 3-4) (4) Weight decreased TRAE (grade 3-4) (4) Dermatitis acneiform TRAE (grade 3-4) (2) Thyroiditis TRAE (grade 3-4) (3) Vomiting TRAE (grade 3-4) (3) Constipation TRAE (grade 3-4) (3) Hypophysitis TRAE (grade 3-4) (3) Gastrointestinal disorders TRAE (grade 3-4) (3) Severe skin reaction TRAE (grade 3-4) (3) Blood creatinine increased TRAE (grade 3-4) (3) Blood and lymphatic system disorders TRAE (grade 3-4) (3) General disorders and administration site conditions TRAE (grade 3-4) (3) Metabolism and nutrition disorders TRAE (grade 3-4) (3) Increase AST TRAE (grade 3-4) (2) Maculopapular rash TRAE (grade 3-4) (2) Pyrexia TRAE (grade 3-4) (2) Hepatobiliary disorders TRAE (grade 3-4) (2) Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) (2) Renal and urinary disorders TRAE (grade 3-4) (2) Hypersensitivity TRAE (grade 3-4) (2) Pancreatitis TRAE (grade 3-4) (2) Nephritis TRAE (grade 3-4) (2) Uveitis TRAE (grade 3-4) (2) Myositis TRAE (grade 3-4) (2) Myocarditis TRAE (grade 3-4) (2) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (2) Skin exfoliation TRAE (grade 3-4) (2) Acute kidney injury TRAE (grade 3-4) (2) Arthralgia TRAE (grade 3-4) (1) Dry skin TRAE (grade 3-4) (1) Dyspnoea TRAE (grade 3-4) (1) Pruritic rash TRAE (grade 3-4) (1) Paraesthesia TRAE (grade 3-4) (1) Cough TRAE (grade 3-4) (1) Myalgia TRAE (grade 3-4) (1) Headache TRAE (grade 3-4) (1) Increased lipase level TRAE (grade 3-4) (1) Chills TRAE (grade 3-4) (1) Peripheral oedema TRAE (grade 3-4) (1) Epistaxis TRAE (grade 3-4) (1) Dyspepsia TRAE (grade 3-4) (1) Hypertension TRAE (grade 3-4) (1) Erythema TRAE (grade 3-4) (1) Urticaria TRAE (grade 3-4) (1) Eczema TRAE (grade 3-4) (1) Pruritus generalised TRAE (grade 3-4) (1) Nervous system disorders TRAE (grade 3-4) (1) Eye disorders TRAE (grade 3-4) (1) Guillain-Barré syndrome TRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (1) Pancytopenia TRAE (grade 3-4) (1) Cardiac disorders TRAE (grade 3-4) (1) Gastritis TRAE (grade 3-4) (1) Sepsis TRAE (grade 3-4) (1) Musculoskeletal and connective tissue disorders TRAE (grade 3-4) (1) Stevens-Johnson syndrome TRAE (grade 3-4) (1) Vascular disorders TRAE (grade 3-4) (1) Rash AE (grade 3-4) (3) Gastrointestinal disorders AE (grade 3-4) (3) Diarrhoea AE (grade 3-4) (2) Increase AST AE (grade 3-4) (2) Weight decreased AE (grade 3-4) (2) Nausea AE (grade 3-4) (2) Vomiting AE (grade 3-4) (2) Abdominal pain AE (grade 3-4) (2) Fatigue AE (grade 3-4) (2) Asthenia AE (grade 3-4) (2) Decreased appetite AE (grade 3-4) (2) Dyspnoea AE (grade 3-4) (2) Hypertension AE (grade 3-4) (2) Stomatitis AE (grade 3-4) (2) Mucosal inflammation AE (grade 3-4) (2) Anaemia AE (grade 3-4) (2) Thrombocytopenia AE (grade 3-4) (2) Neutropenia AE (grade 3-4) (2) Febrile neutropenia AE (grade 3-4) (2) Blood and lymphatic system disorders AE (grade 3-4) (2) Leucopenia AE (grade 3-4) (2) General disorders and administration site conditions AE (grade 3-4) (2) Pneumonitis AE (grade 3-4) (2) Sepsis AE (grade 3-4) (2) Metabolism and nutrition disorders AE (grade 3-4) (2) Nervous system disorders AE (grade 3-4) (2) Renal and urinary disorders AE (grade 3-4) (2) Acute kidney injury AE (grade 3-4) (2) Respiratory, thoracic and mediastinal disorders AE (grade 3-4) (2) Skin and subcutaneous tissue disorders AE (grade 3-4) (2) Vascular disorders AE (grade 3-4) (2) Back pain AE (grade 3-4) (1) Hypothyroidism AE (grade 3-4) (1) Dizziness AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 EAGLE (D vs ICC), 2019 1 CheckMate 141, 2016 2 KEYNOTE-040 (all population), 2018
KEYNOTE-040 (CPS >1), 2018 3 KEYNOTE-048 (P vs C ; all population), 2019
KEYNOTE-048 (P vs C ; CPS > 20), 2019
KEYNOTE-048 (P vs C ; CPS > 1), 2019 1 EAGLE (DT vs ICC), 2019 1 CONDOR (DT vs D ; PDL1 TC<25%), 2019 1 CONDOR (DT vs T ; PDL1 TC<25%), 2019 3 KEYNOTE-048 (PC vs C ; all population), 2019
KEYNOTE-048 (PC vs C ; CPS > 1), 2019
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 cetuximab plus platin plus 5FU vs. durvalumab alone
1.10 [0.83; 1.46] 1.10 [0.83;1.46]cetuximab plus platin plus 5FU vs. durvalumab alone
1.10 [0.83; 1.46] cetuximab plus platin plus 5FU vs. durvalumab plus tremelimumab
1.00 [0.75; 1.32] 1.00 [0.75;1.32]cetuximab plus platin plus 5FU vs. durvalumab plus tremelimumab
1.00 [0.75; 1.32] cetuximab plus platin plus 5FU vs. nivolumab alone
1.43 [0.98; 2.10] 1.43 [0.98;2.10]cetuximab plus platin plus 5FU vs. nivolumab alone
1.43 [0.98; 2.10] cetuximab plus platin plus 5FU vs. pembrolizumab alone
pembrolizumab alone better
1.30 [1.14; 1.47] 1.30 [1.14;1.47]cetuximab plus platin plus 5FU vs. pembrolizumab alone
pembrolizumab alone better
1.30 [1.14; 1.47] cetuximab plus platin plus 5FU vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.47 [1.29; 1.68] 1.47 [1.29;1.68]cetuximab plus platin plus 5FU vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.47 [1.29; 1.68] cetuximab plus platin plus 5FU vs. Standard of Care (SoC)
1.00 [0.82; 1.23] 1.00 [0.82;1.23]cetuximab plus platin plus 5FU vs. Standard of Care (SoC)
1.00 [0.82; 1.23] cetuximab plus platin plus 5FU vs. tremelimumab
0.72 [0.46; 1.13] 0.72 [0.46;1.13]cetuximab plus platin plus 5FU vs. tremelimumab
0.72 [0.46; 1.13] durvalumab alone vs. cetuximab plus platin plus 5FU
0.91 [0.69; 1.20] 0.91 [0.69;1.20]durvalumab alone vs. cetuximab plus platin plus 5FU
0.91 [0.69; 1.20] durvalumab alone vs. durvalumab plus tremelimumab
0.91 [0.72; 1.14] 0.91 [0.72;1.14]durvalumab alone vs. durvalumab plus tremelimumab
0.91 [0.72; 1.14] durvalumab alone vs. nivolumab alone
1.30 [0.90; 1.90] 1.30 [0.90;1.90]durvalumab alone vs. nivolumab alone
1.30 [0.90; 1.90] durvalumab alone vs. pembrolizumab alone
1.18 [0.92; 1.52] 1.18 [0.92;1.52]durvalumab alone vs. pembrolizumab alone
1.18 [0.92; 1.52] durvalumab alone vs. pembrolizumab plus 5FU plus platin
1.34 [0.98; 1.83] 1.34 [0.98;1.83]durvalumab alone vs. pembrolizumab plus 5FU plus platin
1.34 [0.98; 1.83] durvalumab alone vs. Standard of Care (SoC)
0.91 [0.75; 1.10] 0.91 [0.75;1.10]durvalumab alone vs. Standard of Care (SoC)
0.91 [0.75; 1.10] durvalumab alone vs. tremelimumab
0.65 [0.43; 1.00] 0.65 [0.43;1.00]durvalumab alone vs. tremelimumab
0.65 [0.43; 1.00] durvalumab plus tremelimumab vs. cetuximab plus platin plus 5FU
1.00 [0.76; 1.32] 1.00 [0.76;1.32]durvalumab plus tremelimumab vs. cetuximab plus platin plus 5FU
1.00 [0.76; 1.32] durvalumab plus tremelimumab vs. durvalumab alone
1.10 [0.87; 1.39] 1.10 [0.87;1.39]durvalumab plus tremelimumab vs. durvalumab alone
1.10 [0.87; 1.39] durvalumab plus tremelimumab vs. nivolumab alone
1.44 [0.99; 2.09] 1.44 [0.99;2.09]durvalumab plus tremelimumab vs. nivolumab alone
1.44 [0.99; 2.09] durvalumab plus tremelimumab vs. pembrolizumab alone
pembrolizumab alone better
1.30 [1.02; 1.67] 1.30 [1.02;1.67]durvalumab plus tremelimumab vs. pembrolizumab alone
pembrolizumab alone better
1.30 [1.02; 1.67] durvalumab plus tremelimumab vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.47 [1.08; 2.01] 1.47 [1.08;2.01]durvalumab plus tremelimumab vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.47 [1.08; 2.01] durvalumab plus tremelimumab vs. Standard of Care (SoC)
1.01 [0.83; 1.21] 1.01 [0.83;1.21]durvalumab plus tremelimumab vs. Standard of Care (SoC)
1.01 [0.83; 1.21] durvalumab plus tremelimumab vs. tremelimumab
0.72 [0.50; 1.03] 0.72 [0.50;1.03]durvalumab plus tremelimumab vs. tremelimumab
0.72 [0.50; 1.03] nivolumab alone vs. cetuximab plus platin plus 5FU
0.70 [0.48; 1.02] 0.70 [0.48;1.02]nivolumab alone vs. cetuximab plus platin plus 5FU
0.70 [0.48; 1.02] nivolumab alone vs. durvalumab alone
0.77 [0.53; 1.12] 0.77 [0.53;1.12]nivolumab alone vs. durvalumab alone
0.77 [0.53; 1.12] nivolumab alone vs. durvalumab plus tremelimumab
0.70 [0.48; 1.01] 0.70 [0.48;1.01]nivolumab alone vs. durvalumab plus tremelimumab
0.70 [0.48; 1.01] nivolumab alone vs. pembrolizumab alone
0.91 [0.63; 1.30] 0.91 [0.63;1.30]nivolumab alone vs. pembrolizumab alone
0.91 [0.63; 1.30] nivolumab alone vs. pembrolizumab plus 5FU plus platin
1.03 [0.68; 1.54] 1.03 [0.68;1.54]nivolumab alone vs. pembrolizumab plus 5FU plus platin
1.03 [0.68; 1.54] nivolumab alone vs. Standard of Care (SoC)
nivolumab alone better
0.70 [0.51; 0.97] 0.70 [0.51;0.97]nivolumab alone vs. Standard of Care (SoC)
nivolumab alone better
0.70 [0.51; 0.97] nivolumab alone vs. tremelimumab
nivolumab alone better
0.50 [0.30; 0.84] 0.50 [0.30;0.84]nivolumab alone vs. tremelimumab
nivolumab alone better
0.50 [0.30; 0.84] pembrolizumab alone vs. cetuximab plus platin plus 5FU
pembrolizumab alone better
0.77 [0.68; 0.88] 0.77 [0.68;0.88]pembrolizumab alone vs. cetuximab plus platin plus 5FU
pembrolizumab alone better
0.77 [0.68; 0.88] pembrolizumab alone vs. durvalumab alone
0.85 [0.66; 1.09] 0.85 [0.66;1.09]pembrolizumab alone vs. durvalumab alone
0.85 [0.66; 1.09] pembrolizumab alone vs. durvalumab plus tremelimumab
pembrolizumab alone better
0.77 [0.60; 0.99] 0.77 [0.60;0.99]pembrolizumab alone vs. durvalumab plus tremelimumab
pembrolizumab alone better
0.77 [0.60; 0.99] pembrolizumab alone vs. nivolumab alone
1.10 [0.77; 1.59] 1.10 [0.77;1.59]pembrolizumab alone vs. nivolumab alone
1.10 [0.77; 1.59] pembrolizumab alone vs. pembrolizumab plus 5FU plus platin
1.13 [0.94; 1.37] 1.13 [0.94;1.37]pembrolizumab alone vs. pembrolizumab plus 5FU plus platin
1.13 [0.94; 1.37] pembrolizumab alone vs. Standard of Care (SoC)
pembrolizumab alone better
0.77 [0.66; 0.91] 0.77 [0.66;0.91]pembrolizumab alone vs. Standard of Care (SoC)
pembrolizumab alone better
0.77 [0.66; 0.91] pembrolizumab alone vs. tremelimumab
pembrolizumab alone better
0.55 [0.36; 0.86] 0.55 [0.36;0.86]pembrolizumab alone vs. tremelimumab
pembrolizumab alone better
0.55 [0.36; 0.86] pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin better
0.68 [0.59; 0.78] 0.68 [0.59;0.78]pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin better
0.68 [0.59; 0.78] pembrolizumab plus 5FU plus platin vs. durvalumab alone
0.75 [0.55; 1.02] 0.75 [0.55;1.02]pembrolizumab plus 5FU plus platin vs. durvalumab alone
0.75 [0.55; 1.02] pembrolizumab plus 5FU plus platin vs. durvalumab plus tremelimumab
pembrolizumab plus 5FU plus platin better
0.68 [0.50; 0.92] 0.68 [0.50;0.92]pembrolizumab plus 5FU plus platin vs. durvalumab plus tremelimumab
pembrolizumab plus 5FU plus platin better
0.68 [0.50; 0.92] pembrolizumab plus 5FU plus platin vs. nivolumab alone
0.97 [0.65; 1.46] 0.97 [0.65;1.46]pembrolizumab plus 5FU plus platin vs. nivolumab alone
0.97 [0.65; 1.46] pembrolizumab plus 5FU plus platin vs. pembrolizumab alone
0.88 [0.73; 1.06] 0.88 [0.73;1.06]pembrolizumab plus 5FU plus platin vs. pembrolizumab alone
0.88 [0.73; 1.06] pembrolizumab plus 5FU plus platin vs. Standard of Care (SoC)
pembrolizumab plus 5FU plus platin better
0.68 [0.53; 0.87] 0.68 [0.53;0.87]pembrolizumab plus 5FU plus platin vs. Standard of Care (SoC)
pembrolizumab plus 5FU plus platin better
0.68 [0.53; 0.87] pembrolizumab plus 5FU plus platin vs. tremelimumab
pembrolizumab plus 5FU plus platin better
0.49 [0.30; 0.78] 0.49 [0.30;0.78]pembrolizumab plus 5FU plus platin vs. tremelimumab
pembrolizumab plus 5FU plus platin better
0.49 [0.30; 0.78] Standard of Care (SoC) vs. cetuximab plus platin plus 5FU
1.00 [0.81; 1.23] 1.00 [0.81;1.23]Standard of Care (SoC) vs. cetuximab plus platin plus 5FU
1.00 [0.81; 1.23] Standard of Care (SoC) vs. durvalumab alone
1.10 [0.91; 1.33] 1.10 [0.91;1.33]Standard of Care (SoC) vs. durvalumab alone
1.10 [0.91; 1.33] Standard of Care (SoC) vs. durvalumab plus tremelimumab
0.99 [0.82; 1.20] 0.99 [0.82;1.20]Standard of Care (SoC) vs. durvalumab plus tremelimumab
0.99 [0.82; 1.20] Standard of Care (SoC) vs. nivolumab alone
nivolumab alone better
1.43 [1.03; 1.97] 1.43 [1.03;1.97]Standard of Care (SoC) vs. nivolumab alone
nivolumab alone better
1.43 [1.03; 1.97] Standard of Care (SoC) vs. pembrolizumab alone
pembrolizumab alone better
1.29 [1.10; 1.52] 1.29 [1.10;1.52]Standard of Care (SoC) vs. pembrolizumab alone
pembrolizumab alone better
1.29 [1.10; 1.52] Standard of Care (SoC) vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.47 [1.15; 1.88] 1.47 [1.15;1.88]Standard of Care (SoC) vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.47 [1.15; 1.88] Standard of Care (SoC) vs. tremelimumab
0.72 [0.48; 1.07] 0.72 [0.48;1.07]Standard of Care (SoC) vs. tremelimumab
0.72 [0.48; 1.07] tremelimumab vs. cetuximab plus platin plus 5FU
1.39 [0.88; 2.19] 1.39 [0.88;2.19]tremelimumab vs. cetuximab plus platin plus 5FU
1.39 [0.88; 2.19] tremelimumab vs. durvalumab alone
1.53 [1.00; 2.35] 1.53 [1.00;2.35]tremelimumab vs. durvalumab alone
1.53 [1.00; 2.35] tremelimumab vs. durvalumab plus tremelimumab
1.39 [0.97; 1.99] 1.39 [0.97;1.99]tremelimumab vs. durvalumab plus tremelimumab
1.39 [0.97; 1.99] tremelimumab vs. nivolumab alone
nivolumab alone better
1.99 [1.19; 3.35] 1.99 [1.19;3.35]tremelimumab vs. nivolumab alone
nivolumab alone better
1.99 [1.19; 3.35] tremelimumab vs. pembrolizumab alone
pembrolizumab alone better
1.81 [1.17; 2.79] 1.81 [1.17;2.79]tremelimumab vs. pembrolizumab alone
pembrolizumab alone better
1.81 [1.17; 2.79] tremelimumab vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
2.05 [1.28; 3.29] 2.05 [1.28;3.29]tremelimumab vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
2.05 [1.28; 3.29] tremelimumab vs. Standard of Care (SoC)
1.40 [0.93; 2.09] 1.40 [0.93;2.09]tremelimumab vs. Standard of Care (SoC)
1.40 [0.93; 2.09] Standard of Care (SoC) cetuximab plus platin plus 5FU durvalumab alone tremelimumab nivolumab alone pembrolizumab alone durvalumab plus tremelimumab pembrolizumab plus 5FU plus platin direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) cetuximab plus platin plus 5FU durvalumab alone tremelimumab nivolumab alone pembrolizumab alone durvalumab plus tremelimumab pembrolizumab plus 5FU plus platin Standard of Care (SoC) --- 1.00 0.81; 1.231.10 0.91; 1.330.72 0.48; 1.071.43 1.03; 1.971.29 1.10; 1.520.99 0.82; 1.201.47 1.15; 1.88cetuximab plus platin plus 5FU 1.00 0.82; 1.23--- 1.10 0.83; 1.460.72 0.46; 1.131.43 0.98; 2.101.30 1.14; 1.471.00 0.75; 1.321.47 1.29; 1.68durvalumab alone 0.91 0.75; 1.100.91 0.69; 1.20--- 0.65 0.43; 1.001.30 0.90; 1.901.18 0.92; 1.520.91 0.72; 1.141.34 0.98; 1.83tremelimumab 1.40 0.93; 2.091.39 0.88; 2.191.53 1.00; 2.35--- 1.99 1.19; 3.351.81 1.17; 2.791.39 0.97; 1.992.05 1.28; 3.29nivolumab alone 0.70 0.51; 0.970.70 0.48; 1.020.77 0.53; 1.120.50 0.30; 0.84--- 0.91 0.63; 1.300.70 0.48; 1.011.03 0.68; 1.54pembrolizumab alone 0.77 0.66; 0.910.77 0.68; 0.880.85 0.66; 1.090.55 0.36; 0.861.10 0.77; 1.59--- 0.77 0.60; 0.991.13 0.94; 1.37durvalumab plus tremelimumab 1.01 0.83; 1.211.00 0.76; 1.321.10 0.87; 1.390.72 0.50; 1.031.44 0.99; 2.091.30 1.02; 1.67--- 1.47 1.08; 2.01pembrolizumab plus 5FU plus platin 0.68 0.53; 0.870.68 0.59; 0.780.75 0.55; 1.020.49 0.30; 0.780.97 0.65; 1.460.88 0.73; 1.060.68 0.50; 0.92---
pathologies: 276,103,277,102,109,278,101,192,114
- treatments: 875
result logic